Comparative Pharmacology
Head-to-head clinical analysis: THIOGUANINE versus XELODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOGUANINE versus XELODA.
THIOGUANINE vs XELODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioguanine is a purine analog that incorporates into DNA and RNA, inhibiting purine nucleotide synthesis and cell replication. It acts as an antimetabolite, specifically targeting S-phase of the cell cycle.
Prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, incorporates into RNA and DNA, leading to cell death.
2 mg/kg orally once daily for 4 weeks, then 2 mg/kg orally every other day; or 2-3 mg/kg/day orally for 5 days per cycle.
Capecitabine 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles.
None Documented
None Documented
Terminal half-life approximately 11 hours (range 5-16 hours) in adults; extends to 20-30 hours in renal impairment.
Capecitabine: 0.65-0.85 h; 5'-DFCR: 0.9-1.1 h; 5'-DFUR: 0.75-1.0 h; 5-FU: 0.75-1.1 h. Terminal half-life of 5-FU is short, requiring continuous dosing for sustained exposure.
Primarily renal; 40% excreted unchanged in urine within 24 hours; minor biliary/fecal elimination (<10%).
Renal (95.5% as metabolites; 26.1% as parent drug and metabolites, primarily 5'-DFCR, 5'-DFUR, and FBAL); fecal (< 3%)
Category D/X
Category C
Antimetabolite
Antimetabolite